Rare Disease Diversity Coalition Publishes Roadmap to Achieving Health Equity in Rare Disease

On February 26, 2021, Travere Therapeutics was honored to have Linda Goler Blount, president of the Black Women’s Health Imperative (BWHI), present a keynote address at our Rare Disease Day program. The opportunity for Travere team members to hear Linda speak came on the heels of the first meeting of the Rare Disease Diversity Coalition, which is led by BWHI. Read more>
PharmaVoice 100 logo

Travere President and Chief Executive Officer Eric Dube Featured in PharmaVOICE Trend Tracking

April 1, 2020 — The April edition of PharmaVOICE magazine features our CEO Eric Dube, Ph.D., along with other members of the PharmaVOICE 100 leadership community on their top priorities for the remainder of 2021 and the leadership skills that helped guide them through the pandemic. View the digital edition >
RARE-X logo

Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2020 financial results and provided a corporate update.

Read the full press release >
RARE-X logo

Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), EveryLife Foundation for Rare Diseases, Global Genes, and rare disease advocates and patients worldwide in recognizing February 28 as Rare Disease Day 2021.

Read the full press release >

Rare Disease Diversity Coalition Formed To End Racial Disparities In Rare Disease Diagnosis, Research And Treatment

On February 23, 2021, the Black Women’s Health Imperative (BWHI) held the first public meeting of the Rare Disease Diversity Coalition (RDDC) with more than 200 rare disease community members joining together to endorse an ambitious platform of 10 initiatives to achieve tangible solutions to address issues, including delays in diagnosis and treatment for diverse patients. We’re proud to work closely with the leaders of the BWHI to spearhead the formation of the RDDC.
RARE-X logo

RARE-X Announces Patient Community Data Collection, Sharing, and Platform Enhancements with Support from Travere

On February 23, 2021, the nonprofit organization RARE-X announced plans to expand its work helping patient groups collect structured, standardized research-ready data that will better support the development of future treatments. This foundational work is made possible through a funding commitment from Travere Therapeutics.
RARE-X logo

Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the European Commission (EC) has granted orphan designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).

Read the full press release >
Marshall Summar, M.D., CNRDI

Rare Disease Institute Provides Innovative Digital Solutions amidst Pandemic with Support from Travere

Telehealth-first care. That’s the approach that many clinics and health centers adopted for preventative and follow up visits in the wake of the pandemic’s arrival. Online and on-phone visits enable healthcare professionals and their patients to manage conditions without the burden of travel or undo risk of exposure to the coronavirus.
RARE-X logo

Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

SAN DIEGO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company’s ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) achieved its pre-specified interim FSGS partial remission of proteinuria endpoint (FPRE) after 36 weeks of treatment.

Read the full press release >
RARE-X logo

Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy

SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).

Read the full press release >